Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Astellas Unloading 16 Off-Patent Brands to LTL Pharma
Joining a list of major drug makers unpacking their off-patent brand-name drugs, Astellas Pharma will transfer 16 long-listed products (LLPs) including the peptic ulcer med Gaster (famotidine) to LTL Pharma, a newly launched company in Japan dedicated to the LLP…
To read the full story
Related Article
- Astellas to Offload Seroquel, “G1” LLP, to LTL Pharma
January 17, 2025
- Pricing Revamp for Off-Patent Brands “Within Our Expectation”: LTL Pharma CEO
February 13, 2018
- LTL Pharma to Take Over 3 Brands from Astellas in October
August 3, 2017
- Astellas’ LLP Sale to Private Equity Group Signals New Business Model for Older Drugs
April 10, 2017
BUSINESS
- Organon Dysmenorrhea Drug Mercilon Set for Sept. 1 Launch
August 18, 2026
- Pfizer, BioNTech Win Japan Nod for XFG-Adapted COVID Vaccines
August 18, 2026
- Chiba Downpours Cause No Major Disruption to Drug Operations
August 17, 2026
- Chugai Files Tecentriq for Colon Cancer Adjuvant Therapy in Japan
August 17, 2026
- Enflonsia Filed for High-Risk Children in 2nd RSV Season in Japan: MSD
August 17, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…